Get the Stockscreener App
30.02
0.03%
-0.025
Apellis Pharmaceuticals Inc stock is traded at $30.02, with a volume of 653.01K.
It is down -0.03% in the last 24 hours and up +32.63% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$30.05
Open:
$30.24
24h Volume:
653.01K
Relative Volume:
0.27
Market Cap:
$3.79B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-14.79
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+6.75%
1M Performance:
+32.63%
6M Performance:
+64.96%
1Y Performance:
+9.60%
1-Day Range:
$29.53
$30.24
1-Week Range:
$28.05
$30.48
52-Week Range:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
30.03 | 3.80B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.18 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.20 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.82 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.50 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.53 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Earnings To Watch: Apellis Pharmaceuticals Inc (APLS) Reports Q3 2025 Result - GuruFocus
Apellis Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-29 02:11:34 - newser.com
How moving averages guide Apellis Pharmaceuticals Inc. tradingJuly 2025 Pullbacks & Capital Protection Trading Alerts - newser.com
Why retail investors favor Apellis Pharmaceuticals Inc. stockJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - Fundação Cultural do Pará
Apellis Pharmaceuticals Inc. stock prediction for this weekQuarterly Profit Summary & Long-Term Capital Growth Ideas - newser.com
Will a bounce in Apellis Pharmaceuticals Inc. offer an exitWeekly Gains Summary & Safe Entry Point Identification - newser.com
Is Apellis Pharmaceuticals Inc. stock attractive for income investorsEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recoveryLong Setup & Detailed Earnings Play Alerts - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performancePortfolio Return Report & Entry and Exit Point Strategies - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Performance Summary & Technical Entry and Exit Tips - newser.com
What valuation ratios show for Apellis Pharmaceuticals Inc. (1JK) stockMarket Performance Recap & Advanced Technical Signal Analysis - newser.com
Will Apellis Pharmaceuticals Inc. (1JK) stock rise with strong economyWeekly Gains Report & AI Powered Market Trend Analysis - newser.com
Will Apellis Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedWeekly Trade Report & High Yield Equity Trading Tips - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.Market Risk Analysis & Consistent Return Strategy Ideas - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock survive global slowdownQuarterly Trade Summary & Verified Entry Point Signals - newser.com
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.Quarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com
Can Apellis Pharmaceuticals Inc. stock sustain market leadership2025 Market Outlook & Weekly Breakout Watchlists - Fundação Cultural do Pará
How Apellis Pharmaceuticals Inc. stock performs in weak economyMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Will Apellis Pharmaceuticals Inc. stock gain from lower inflation2025 Price Targets & Reliable Breakout Stock Forecasts - newser.com
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apellis Pharmaceuticals Inc Stock (APLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Timothy Eugene | Chief Financial Officer |
Oct 21 '25 |
Sale |
28.03 |
10,000 |
280,300 |
110,936 |
1.48%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):